News from Bayer
August 08, 2022
Not intended for U.S. and UK Media
U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
August 04, 2022
Second quarter of 2022
Bayer: Strong growth, outlook raised
August 02, 2022
Bayer Consumer Health leaders propose new principles for science-led self-care